Rare inherited diseases of copper metabolism
This year, Randox Reagents are supporting Rare Disease Day on 28th February. Randox offer a test that aids in the diagnosis and monitoring of Wilson Disease and Menkes Disease which are rare inherited disorders of copper metabolism.
What is a rare disease?
According to the European Union, a rare disease is defined as a disease that affects less than 5 in 10,000 of the general population. 7% of the population will be affected by a rare disease at some point in their life. This equates to 30 million people in Europe.
Wilson Disease is a rare inherited autosomal recessive disorder of copper metabolism, characterised by excessive deposition of copper in various bodily tissues, particularly the liver, brain, and corneas of the eyes. This is due to mutations of the ATP7B gene which is responsible for encoding specific proteins that are responsible for the transportation of copper from the liver around the body, which is prohibited due to the mutations. If left untreated, Wilson Disease can cause hepatic disease, central nervous system dysfunction, or death. Approximately 1 in 30,000 people are affected by Wilson Disease worldwide (WDA, 2018). The first sign of Wilson Disease is liver dysfunction in more than half of patients, beginning at six years of age, however, it usually presents clinically in teenage years or early twenties manifesting as acute hepatitis. Some individuals with Wilson Disease have been thought to have infectious hepatitis or infectious mononucleosis and so it is vital that those with unexplained, abnormal liver tests are tested for Wilson Disease.
Menkes Disease is more likely to affect premature babies and is a rare inherited x-link recessive disorder of copper metabolism, characterised by sparse, kinky hair; failure to gain weight and grow at the expected rate (failure to thrive); and deterioration of the nervous system. This is due to mutations of the ATP7A gene which is responsible for the absorption of copper from food in the small intestines and supplying copper to certain enzymes that are critical for the structure of bone, skin, hair, blood vessels, and the nervous system. Approximately 1 in 100,000 people are affected by Menkes disease worldwide (USA National Library of Medicine, 2018). The first sign of Menkes Disease develops at 2-3 months of age and includes curly, sparse, coarse, dull, and discoloured haired.
As there are no cures for Wilson Disease or Menkes Disease, treatment aids to reduce/replace copper within the body. The Randox Copper assay can comfortably detect copper levels outside of the healthy range to aid in the diagnosis and monitoring of treatment of Wilson Disease and Menkes Disease.
Randox Copper Assay
The Randox Copper assay is used to measure the amount of copper in the blood; to help with the diagnosis and monitoring of rare inherited diseases related to copper toxicity (Wilson Disease) and copper deficiency (Menkes Disease). Copper deficiency is less likely because a normal diet contains plenty of copper including organ meats, beans, and wholegrains, however, copper deficiency is more likely to occur in those who are malnourished, more likely children.
For more information visit: https://www.randox.com/copper
To request an application for your specific analyser, contact email@example.com
Randox are proud to announce that Randox Teoranta, for the fourth year running, is the main sponsor for WAAR 2018, an event which places mental wellbeing at its core. Launched at the weekend, on Friday 23rd February 2018, this year’s Wild Atlantic Adventure Race promises to deliver an incredible display of stamina, strength and perseverance as outdoor pursuit enthusiasts once again brave the elements to complete the demanding 55.5km course or 39km sprint.
The full Wild Atlantic Adventure Race (WAAR) features a 10km run, 42.5km cycle, 2km hike and 1km kayak, starting and finishing at CLG Naomh Muire, The Banks, Mullaghderg, Co. Donegal on Saturday 12th May 2018. Set along one of the most beautiful natural coastlines in the world, the west coast will once again play host to one of the most challenging yet enjoyable races, featuring both novice and elite individuals, as well as several relay teams.
This year, fundraising efforts will be donated to CLG Naomh Muire. Launching the event was best-selling author and TV personality Majella O’Donnell who overcame breast cancer in 2013.
Hailing from Co. Tipperary and married to Irish country music legend Daniel O’Donnell, Majella became iconic in her own right when she shaved her head live on The Late Late Show in 2013, raising €600,000 for The Irish Cancer Society. Majella also documented her life story in her book ‘It’s All in the Head.’ The book’s moving tale quickly became a number one Irish best-seller and 2014 Irish Book Award-winner.
Majella’s own force of character and deep-seated determination makes her a worthy representative to launch WAAR 2018, an endurance race that will test the physical and mental stamina of participants to their limits.
Dr. Ciaran Richardson, Head of Research & Development at Randox Teoranta in Dungloe, said:
“We are delighted to, once again, partner with WAAR. The event is a real test of physical wellbeing and here at Randox, we take our on-going work to promote positive physical and mental health very seriously. In the last few years, our labs in Dungloe have led the way in world-leading diagnostic research in a wide range of areas including Alzheimer’s disease, kidney disease, cancer, gastrointestinal disorders and stroke.
The WAAR launch was a great success and we look forward to the exciting event in May. We encourage as many people as possible to get involved as it’s sure to be another thrilling event for both entrants and spectators alike.”
For further information please contact the Randox PR Team: phone 028 9442 2413 or email firstname.lastname@example.org
Randox Clinical Laboratory Services is a dedicated group of laboratories across the United Kingdom with plans to expand across the world. All of the clinical laboratories are purpose built to deal with the bespoke needs of research and clinical projects. Currently we have laboratories situated in Antrim, Holywood, Liverpool and London.
Flexibility and quality are at the core of our service offering and our experienced team are available to support and advise at each step of a project to ensure deadlines are met and high quality data is delivered in the most cost efficient manner.
Specialising in biomarker and multiplex testing in addition to standard safety and clinical testing, RCLS provides a full laboratory service to accelerate your project to completion. Our patented and globally recognised Biochip Array Technology (BAT), provides multiplex testing solutions in an accurate and precise format. Vast expertise in in-house antibody and assay development also allows for customised assays to be incorporated into your testing.
A key focus for RCLS, utilising this technology (BAT) and the ability to customise, is esoteric/niche biomarker analysis within clinical trials. Randox has been providing custom assay design, development and manufacturing services to the diagnostic, pharmaceutical, contract research and biotech industries for many years. This also includes fully customised human and animal quality control sera. We have the facilities to design a novel multiplex biochip tailored to each customer’s requirements taking into account sample types, available sample volumes and expected ranges for various analytes of interest.
Our assay development specialists will endeavour to work with you to ensure your needs are constantly met and provide a smooth process from the time of your first enquiry through to final delivery.
If you would like more information on RCLS please contact email@example.com
A record £50 million investment which will deliver cutting-edge technologies to diagnose conditions like cancer, heart conditions and infectious diseases has been announced by Northern Ireland diagnostics company Randox Laboratories and Invest Northern Ireland.
This major project involves the establishment of three Centres of Excellence, enabling Randox R&D scientists to work collaboratively with colleagues from Queen’s University Belfast and Ulster University. The centres are being officially launched today at the Randox Science Park. The ceremony will include a keynote address from Sir John Bell, who chaired the UK Government’s Life Sciences Industrial Strategy Board.
Advanced diagnostics have been identified as key to delivering sustainable improvement to healthcare systems struggling to cope with increasing levels of chronic and preventable conditions. Having been focused in this field for over 36 years, Randox has a successful track record of developing new and innovative tests – examples include assessing those at risk of Alzheimer’s disease and genetic cardiac conditions, to promote and enable preventive treatment, and a new clinically-approved test to diagnose prediabetes.
Managing Director of Randox Laboratories, Dr Peter FitzGerald, who today launched the three Centres of Excellence, said;
“When almost a quarter of the deaths of people under 75 in the UK are considered preventable, we need to ask ourselves what can be done to improve healthcare outcomes. There is an undeniable case for radical change in the way healthcare is delivered, and sophisticated diagnostics will be at the fore of this revolution.
“Enabling earlier and more accurate diagnosis, to identify those at the earliest stages of illness, ideally before the onset of any symptoms, is a game-changer. Through early intervention we can restrict the development of chronic conditions and improve people’s lives. Our view of the future is one where people are empowered through earlier diagnosis to stay healthier for longer, and where healthcare systems are freed to deliver quality services to patients. Our announcement today demonstrates our continuing commitment in this field.
“We are grateful for the support offered by Invest NI and look forward to addressing these pressing healthcare needs.”
The Centres of Excellence will focus respectively on clinical diagnostics, engineering for biosciences and quality control. The project, which will strengthen collaborative partnerships between Randox, Queen’s University Belfast and Ulster University, will accelerate the development of new technologies and drive healthcare improvements regionally, nationally and across the globe.
Of the £23m of support offered by Invest NI, £5m will go toward research projects at Ulster University and Queen’s University Belfast.
Welcoming the investment, Alastair Hamilton, Chief Executive of Invest NI said;
“Randox has a long history of investing heavily in innovation and R&D which has enabled it to create a globally competitive export driven business, capable of developing world leading research. This major investment will enable Randox to perform cutting-edge R&D which has the potential to revolutionise the global healthcare industry. This is excellent news for Northern Ireland’s life and health sciences sector. Northern Ireland is enjoying a growing international reputation as a region of expertise and knowledge in key areas such as Diagnostics, Precision Medicine and Advanced Manufacturing. The three new Centres of Excellence will help build on this and enhance Northern Ireland’s credibility, provide supply chain opportunities, and encourage knowledge transfer with our universities.”
Sir John Bell, commenting on the potential for the UK Life Sciences sector said;
“The life sciences industry represents one of the dominant economic sectors in the UK, and one with considerable potential for growth. However, whilst we have many natural strengths we cannot afford to be complacent. We must strive to optimise our science base, to encourage collaboration across academia, industry and the NHS, and grow our industrial capabilities. To do so we need to use our extensive data sets to best effect, and have in place a strong skills strategy. Success requires vision and drive. To that end I would like to congratulate Dr FitzGerald and Randox in the establishment of these three R&D collaborative Centres of Excellence – these are assets of national standing and will have a meaningful impact in enabling earlier and more accurate diagnosis, driving improvements in patient care, regionally, nationally and globally. They are leaders in this field, committed to innovation, and I wish them every success.”
Professor Jim McLaughlin, Director of Ulster University’s Nanotechnology and Integrated Bioengineering Centre, added;
“This very welcome investment enables pioneering Randox-inspired engineering capacity at Ulster University and reflects our research commitment to the life sciences industry. From nanotechnology to the development of systems that will enable large scale laboratory capability to be produced in the palm of your hand, the partnership brings shared industry and academic research excellence from the lab into the marketplace. Life sciences is a vital economic sector locally and this collaboration will advance diagnostics and ultimately enhance patient health outcomes.”
Dr David Jess, Senior Lecturer at Queen’s University Belfast School of Mathematics and Physics, added;
“The Randox Centres of Excellence will allow Queen’s University Belfast to continue to deliver cutting-edge and world leading research. We look forward to collaborating further with industry to develop pioneering research, focused on the needs of society.”
Invest NI’s R&D support is part funded by ERDF under the EU Investment for Growth and Jobs Programme 2014 – 2020.
For further information please contact the Randox PR Team: phone 028 9442 2413 or email firstname.lastname@example.org
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. It requires a small sample volume and generates results in less than 20 minutes. The process from sample entry to results can be completed in 3 simple steps, with minimum room for human error.
The MultiSTAT offers a very simple drug screening solution to those who have no knowledge of laboratory procedures through combining simplicity with cutting-edge innovation. It is this innovative technology that enables the MultiSTAT to be easy to use, yet extremely powerful.
Whether testing is needed for new entrants going into prison, or for a drug drive test – the MultiSTAT is adaptable for use across a range of different applications. As an analyser, it can deliver highly accurate and reliable laboratory quality results. Its ability to provide these quickly and over a wide range of substances makes it as flexible as any point of care test. The Evidence MultiSTATs ease of use makes it accessible to all with no previous laboratory experience required.
The Evidence MultiSTAT is a versatile analyser that provides automated drugs screening in a range of settings, such as low throughput laboratories, workplaces and police stations. Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results and offers a highly sensitive way to detect drugs of abuse.
The MultiSTAT facilitates on-site simultaneous screening of multiple drug classes, including classical, prescription and synthetic drugs of abuse. Available matrices include oral fluid, with blood and urine coming soon.
Recently, the InfiniPlex for Milk Array has been developed by Randox Food Diagnostics to help the dairy industry improve the global standards of dairy. Complying with 98% of EU regulated antibiotics, InfiniPlex is currently unrivalled in the market with the ability to simultaneously detect anti-parasitics, anti-inflammatories and unauthorised substances found in dairy products from a single sample of raw milk using Biochip Array Technology. With results screened in just under 20 minutes, the Evidence MultiSTAT is ideally suited to the fast-paced nature of the dairy industry.
Developed with the user in mind, no technical expertise is required to use the test and is available on two analysers in the Evidence Series, the Evidence MultiSTAT and Evidence Investigator.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
Your heart is amazing. Not only is it your most critical organ but also one of the most hard-working. The average adult heart beats around 100,000 times a day, acting as a giant pump for all the blood in your body. Indeed, every day your heart pumps over nine litres of blood through a system of blood vessels over 60,000 miles long – it’s little wonder, then, the importance placed on looking after such a vital muscle.
The heart works 24/7, only taking a rest when you sleep with the natural drop of heart rate and blood pressure. Over time, and influenced by lifestyle choices, the heart grows weaker, needing to work harder to fulfil its function. Crucial lifestyle changes now could limit your risk of developing serious cardiac conditions, such as Cardiovascular Disease (CVD) in the future. Factors which can contribute to your CVD risk include genes inherited from parents or grandparents, smoking, an unhealthy diet, excessive alcohol consumption and low physical activity levels.
You can’t change your DNA, but you can find out what it means to you and your family. One of our advanced tests can identify people living with a common but often hidden disorder – Familial Hypercholesterolemia (FH). Fewer than 12% of people in the UK know they have this potentially fatal condition. It is characterised by dangerously high levels of cholesterol which can lead to early onset cardiovascular disease.
While lifestyle changes may help to limit your risk of CVD, and related heart condition, it is impossible to eradicate it completely for everyone. Accounting for 31% of deaths worldwide, CVD is the number one cause of death globally but early screening could lower this figure significantly. That’s why it’s vitally important to detect CVD early before a coronary event like a heart attack occurs.
Today in the UK, 530 people will go to the hospital with a suspected heart attack. Only a fifth of these people will actually be having a heart attack. According to a team from King’s College London, as reported by the BBC, a faster, more accurate diagnosis of whether chest pain is caused by a heart attack would save the health service millions of pounds each year by sending well patients home and freeing up beds. Yet current testing methods do not efficiently differentiate between high-risk patients and the estimated 80% of patients who are not having a heart attack.
Randox’s revolutionary test for Heart-Type Fatty Acid-Binding Protein (H-FABP), when combined with current testing, is able to rule out a heart attack for patients who present at A&E with chest pain which is caused by other conditions such as respiratory issues, meaning they may not need emergency admission.
When measured at the time a patient presents to A&E with chest pain, H-FABP enables doctors to triage patients suffering with a heart attack more efficiently than before, making sure those at high-risk are given medical intervention earlier.
Early screening in the form of a comprehensive health check is essential to detect cardiac irregularities before they become serious problems. Heart damage builds up over time, meaning that when detected early enough, lifestyle changes can help to reduce cardiac risk and potentially even prevent a cardiac event occurring.
Therefore, it is vitally important that individuals are tested for CVD to detect them in the earliest stages to reduce damage, prevent further damage, or even death. Furthermore, many people suffer from inherited cardiac risk factors, which stresses the need for accurate testing.
Randox offer the complete laboratory solution to cardiac risk assessment information to doctors and hospitals, and also directly to the public at Randox Health. Our range of both traditional and novel cardiac risk biomarkers, along with our technologically-advanced range of analysers, serves to allow us to offer the most advanced, most accurate health check available on the planet.
As well as your cardiovascular risk score, a Randox Health check will also assess your cholesterol levels, FH risk, triglycerides, creative kinase, myoglobin, troponin levels and many more heart health indicators. In total, a Randox Health check can assess up to 350 different markers of irregularity or disease in the whole body, from heart to hormone health and skin to stomach.
Many serious future health issues are preventable now with action. Find out more about our health check programmes here.
About Randox Health
Randox Health is a global leader in healthcare diagnostics; today more than 5% of the world’s population – in excess of 370 million people across 145 countries – receives medical diagnosis using Randox products each year.
After investing over £220 million in the invention and production of revolutionary blood-science technology, a single Randox Health check will deliver a complete picture of your health – as it is now and, crucially, how it is likely to develop in the future.
Randox Health has proven that signs of disease or irregularity can be caught at their earliest stage. This means that, with early action, some cases of illness can even be prevented altogether. Our health checks include, but are not limited to, cancer surveillance, fertility monitoring, heart health, nutrition, digestive and diabetes health.
In other words, from one health check, you’ll receive up to 350 results and afterwards avail of expert advice from the Randox scientists or a Randox Health GP. Not only that, but a complete 12-month programme and repeat testing come as standard so you can have full confidence that you are really taking care of yourself.
Find out more information about Randox Health checks here: https://www.randoxhealth.com/our-packages/
Randox has developed the RX series range of clinical chemistry analysers for high-quality semi-automated and fully automated testing. Choose between the RX misano, RX monaco, RX daytona+, RX imola, and the RX modena depending on the throughput of your laboratory. The RX series offers a suitable analyser for your laboratory’s needs. For more information on the Randox RX series, please click here or email email@example.com
Randox offers an extensive range of third party diagnostic reagents which are internationally recognised as being of the highest quality; producing accurate and precise results. We have the largest test menu of 118 assays, covering over 100 disease markers including specific proteins, lipids, therapeutic drug monitoring, drugs of abuse, antioxidants, coagulation, diabetes and veterinary testing. A wide range of formats and methods are available providing greater flexibility and choice for any laboratory size. In addition to flexible pack sizes and a comprehensive list of analyser applications, we can also provide dedicated reagent packs (Randox Easy Read and Easy Fit regents) for a wide range of chemistry analysers providing you with freedom of choice from an independent manufacturer.
Acusera – Internal Quality Control
The Acusera cardiac controls have been designed to cover a wide range of cardiac markers at clinical decision levels, eliminating the extra expense of an additional low level control. The controls are available in a both liquid ready-to-use and lyophilized formats making them ideal for all situations and manufactured from 100% human serum a matrix similar to that of the patient is guaranteed. For more information on the Randox Acusera internal quality control, please click here or email firstname.lastname@example.org
RIQAS – External Quality Control
The RIQAS Liquid Cardiac EQA programme is designed to monitor the performance of up to 9clinically significant cardiac markers including: CK-MB mass, D-dimer, Digoxin, homocysteine, hsCRP, myoglobin, NT proBNP, troponin I, and troponin T. RIQAS is ISO/IEC 17043 accredited and allows the registration of up to five instruments at no extra cost. All samples are 100% human serum and provided in a liquid ready-to-use format for enhanced convenience. Submit your results bi-weekly and view reports online via RIQAS.Net. For more information on RIQAS, the world’s largest international EQA scheme, please click here or email email@example.com
For further information, please contact the Randox PR team via email: firstname.lastname@example.org or phone 028 9442 2413
Alprazolam, also known as the trade name Xanax, is a widely prescribed anxiety drug in the US. Alprazolam is a minor tranquilliser which can cause sedation, short term memory loss and depress the nervous system, slowing down the brain and body. Recommended for short term use, the drug can be highly addictive and only be obtained on private prescription in the UK.
People have been known to crush or melt the dangerous tranquilliser that comes in a tablet form, to inject the substance. Extremely dangerous and fatal, the chalk in the tablets can cause collapsed veins and lead to an abscess and infection.
A recent article by BBC News uncovered that Alprazolam is being purchased online and abused by children as young as 13. The news comes after reports of social media sites being used to buy dangerous substances and locate drug dealers. In 2017, up to 20 teenagers from Wiltshire needed treatment after using Alprazolam. This year in Sussex alone, several young people have been admitted to hospital after taking the prescription drug.
A spokesperson from Pfizer, a Xanax manufacturer, expressed concerns over the alarming rise of counterfeit Xanax drugs and the growing availability on the dark web. Discussing the issue, they mentioned that ingredients such as boric acid, heavy metals and floor polish have been found in counterfeit Xanax medications. Defined as “part of our youth culture” Nick Hickmott from Addaction states, it is currently debatable how many people are currently using Alprazolam. London’s MP Bambos Charalambous has called for awareness campaigns and further research to be conducted in order to support services.
Alprazolam is not the only widely abused prescription drug, as criminal gangs were reported smuggling tens of millions of prescription drugs out of the UK’s protected supply chain. Northern Ireland have also expressed concerns over the rise of pregabalin, with BBC spotlight revealing a 46% rise from a data base of 20 million prescription records written by GPs across the country in the past four years. However, the biggest killer in Northern Ireland is tramadol, a prescription painkiller taken by thousands daily.
Randox Toxicology offer the most comprehensive drugs of abuse test menu across multiple forensic matrices. Our level of expertise in toxicology has enabled us to provide the DoA ULTRA panel, which can screen for a wide range of prescription drugs of abuse, including Alprazolam and Tramadol. Using our revolutionary Biochip Array Technology, Randox Toxicology provide a complete immunoassay profile in the initial screening phase.
For further information, please contact the Randox PR team via email: email@example.com or phone 028 9442 2413
With Valentine’s Day being in the heart of National Heart Month, Randox Biosciences want to take this opportunity to talk about the importance of looking after your heart and the awareness of the tests out there currently on offer.
The British Health Foundation launched National Heart Month with the aim to spread awareness of heart disease and to encourage the nation to make small changes towards a healthier lifestyle.
Currently Coronary Heart Disease (CHD) is the leading cause of death in the UK, with 73,000 people dying from Coronary Heart Disease every year in the UK.1
Coronary Heart Disease is a disease in which plaque builds up inside the coronary arteries. Our arteries supply oxygen-rich blood to the heart muscles, however, over time plaque builds up and can harden. This hardened plaque, then narrows the coronary arteries reducing the flow of oxygen-rich blood to the heart, which can lead to angina or a heart attack to occur.2
CHD is more likely with increasing age, in men rather than in women before menopause and if close relatives have suffered CHD early in life. These risk factors cannot be changed, however, there are other risk factors that can be modified. These are known as elevated blood cholesterol, overweight and obesity, smoking, lack of physical activity, unhealthy diet and stress.
You can prevent and control many CHD risk factors with heart-healthy changes and medication. There is only a few risk factors that can’t be controlled such as your age, gender and family history. Nonetheless, many lifestyle changes help control several CHD risk factors at the same time, such as physical activity which may reduce stress, lower your blood pressure, help control diabetes and help control your weight.
If you believe you are at risk of coronary heart disease, you can ask for a risk assessment for heart diseases, heart attack or stroke. However, current CHD risk assessment tools based on common risk factors such as blood pressure and blood cholesterol levels have low predictive value and take no account of genetic predisposition to CHD.
In recent years, Genome Wide Association Studies (GWAS) have been carried out to identify genetics variants associated with CHD. Meta-analysis of such studies has identified 19 variants as being associated with CHD.
Individually, the presence of an “at risk” variant does not greatly increase the risk of developing CHD. However, the presence of multiple “at risk” alleles can increase the risk of developing CHD two-fold or greater an effect similar to being a current smoker. Combining genotype information with common risk factors could allow individuals to be more accurately classified therefore preventative therapies and lifestyle advice can be targeted to those who require it most.
In order to utilise the GWAS findings within a clinical setting, individuals require to be genotyped for each of the 19 CHD “at risk” SNPs. However, at present this can be a time consuming and expensive process.
Together with key opinion leaders in cardiovascular genetics, Randox has developed the Cardiac Risk Prediction Array which will allow all 19 SNPs to be genotyped simultaneously, which incorporates a test to identify patients predisposed to statin induced myopathy.
Firstly, a multiplex PCR reaction is performed, where the products amplified correspond to the genotype of the patient sample. The PCR products are then hybridised onto the Cardiac Risk Prediction biochip array and imaged using the Evidence Investigator analyser to identify which PCR products are present. Patient samples can be genotyped within 1 day.
This Heart Month, we are urging the pubic to not only help raise awareness of heart disease but also educate themselves on the signs and symptoms to increase early diagnosis. As a global diagnostic company, Randox Biosciences are committed to the ongoing development of diagnostic tests, as well as our research into numerous disease areas to improve health worldwide.
To find out more email us at firstname.lastname@example.org
1 – HeartUK
2 – National Heart, Lung and Blood Institute
Acetaminophen is a commonly used medicine for pain-relief. During cold and flu season, it is common to resort to pain-relief medicines to relieve headaches, and ache and pain symptoms associated with a cold or flu as there is no cure. However, the therapeutic range for acetaminophen is 10-30 mg/l, which is small and very easy to go over. During cold and flu season, it is important to monitor the amount of paracetamol entering your body as acetaminophen is more dangerous than suspected. At therapeutic levels, acetaminophen does not produce any adverse effects, however, long-term treatment, prolonged use, and taking a few more than the recommended dose can be severely damaging and fatal. Accidental acetaminophen overdose took the lives of 1,500 people in the U.S between 2001 and 2010. The Randox Acetaminophen assay is used to determine the concentration levels of acetaminophen in the blood to determine if an overdose has taken place.
It is commonly recognised that acetaminophen overdose causes hepatotoxicity, but it is less commonly recognised that it can also cause nephrotoxicity in less than 2% of patients. Nephrotoxicity is toxicity of the kidneys and is often associated with a reduced amount of glutathione which is important for normal cellular metabolism in the kidneys. The Randox Glutathione Reductase assay is required for the regeneration of reduced glutathione. Glutathione is often discussed in association with the Randox Glutathione Peroxidase, which requires reduced glutathione for activation. Both Glutathione reagents are unique to Randox.
Acute renal failure due to acetaminophen manifests as acute tubular necrosis, which can occur alone or in combination with hepatic necrosis. Nephrotoxicity can also occur when the therapeutic levels of acetaminophen are not exceeded. This most commonly occurs when acetaminophen is taken in combination with alcohol. Upon testing acetaminophen levels and the results fall within the therapeutic range, the Randox Ethanol assay can test alcohol levels to determine if a combination of alcohol and acetaminophen caused nephrotoxicity. Renal impairment may be more common than previously suspected as acute renal failure occurs in 10-40% of patients with severe hepatic necrosis. Upon testing acetaminophen to determine toxicity, Randox also offer the following renal tests to test for nephrotoxicity:
For more information visit: https://www.randox.com/acetaminophen
To request an application for your specific analyser, contact email@example.com
Here at Randox, we’re a diverse bunch, spread over 145 countries in the world. We have more than 1400 employees of 44 nationalities, including 300 research scientists and engineers. Needless to say, the Randox family is a multicultural one!
We have four key manufacturing and R&D sites – in County Antrim, Northern Ireland; Dungloe, County Donegal, Ireland; Bangalore, India; and the Greater Washington DC area, in the U.S. This month, our We Are Randox article focuses on the team in Bangalore.
Randox India, located alongside other high-tech industries based in Bangalore, consists of 37 office staff and 77 field staff, including customer support engineers and sales managers. A base for administration, sales and manufacturing in India, the Bangalore site, set in the capital of the Indian state of Karnataka, services the 3.3 million square kilometre country.
Photographed are members of the Randox team in Bangalore from the following departments;
- Accounts and Finance
- Customer Support Engineers
- Logistics and Trading
- Quality Control
- Research & Development
- Human Resources
Brian Walsh, Manufacturing Manager at Randox India, said:
“The photograph below was taken during this year’s Diwali, which is the Hindu festival of lights celebrated every year in autumn in the northern hemisphere. Danny Maguire, who is based in Ardmore at Randox HQ, was over on business at the time and joined us in celebrating this cultural tradition.
“It is one of the most popular festivals of Hinduism, and spiritually signifies the victory of light over darkness, good over evil, knowledge over ignorance, and hope over despair.
“We all really enjoyed having Danny with us and sharing some of our customs and values with him, many of which our team members based in other sites across Randox would not know about.
“We hope to welcome many more of our colleagues from across the globe to Randox India in the near future!”
Want to know what it’s like to work in Bangalore? Read all about when we met up with Pankaj Chitkara, who is our National Sales Manager for the RX Series in India.
For further information on the Randox Bangalore team, please contact the Randox PR team via email: firstname.lastname@example.org or phone 028 9442 2413